<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184676</url>
  </required_header>
  <id_info>
    <org_study_id>P130405</org_study_id>
    <secondary_id>ID RCB : 2014-A00453-44</secondary_id>
    <nct_id>NCT02184676</nct_id>
  </id_info>
  <brief_title>T1D Risk Assessment in Kids With Relatives</brief_title>
  <acronym>TRAKR</acronym>
  <official_title>Early Immunological, Metagenomic, Metabolic and Environmental Factors in the Progression to Type 1 Diabetes: the TRAKR Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé et de la Recherche Médicale (INSERM) U1016 - Institut Cochin, Immunology of Diabetes Team, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSERM U1153, Epidemiology Research Unit on Perinatal Health and Women and Children Health, Port-Royal Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commissariat A L'energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether early immunological markers (activation of&#xD;
      autoreactive T lymphocytes) precede and are predictive of the appearance of autoantibodies in&#xD;
      children born from type 1 diabetic parents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of type 1 diabetes (T1D) is estimated between 0.2 and 0.4% in France. The&#xD;
      incidence in France is more than 10/105 per year, with a steady increase (~4%/year),&#xD;
      especially in children. Infants born to parents with T1D have a 15-fold higher risk to&#xD;
      develop T1D compared to the general population. The appearance of autoantibodies precedes and&#xD;
      is highly predictive of the later occurrence of T1D. The activation of B lymphocytes, which&#xD;
      produce autoantibodies, is controlled by T helper lymphocytes. Hence, biomarkers associated&#xD;
      with initial T lymphocyte activation are likely to precede the appearance of autoantibodies.&#xD;
&#xD;
      The aim of the TRAKR study is to determine whether the appearance of autoreactive T&#xD;
      lymphocytes is predictive of the emergence of autoantibodies.&#xD;
&#xD;
      The secondary objectives are: 1) to evaluate whether metagenomic, metabolic, or environmental&#xD;
      factors are associated with the appearance of autoantibodies; 2) to evaluate the incidence&#xD;
      and the time of autoantibody appearance in a French population of genetically at-risk&#xD;
      children; 3) to compare the incidence of autoantibodies between infants born to T1D fathers&#xD;
      and mothers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2015</start_date>
  <completion_date type="Actual">May 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autoreactive T lymphocytes</measure>
    <time_frame>48 months</time_frame>
    <description>presence, frequency, antigen specificity, phenotype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metagenomic signatures</measure>
    <time_frame>48 months</time_frame>
    <description>presence, frequency, type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic signatures</measure>
    <time_frame>48 months</time_frame>
    <description>presence, frequency, type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental factors</measure>
    <time_frame>48 months</time_frame>
    <description>Sociodemographic characteristics, e.g. age, gender, occupation, living place, family situation, number of children, education, housing type, animal contact&#xD;
Family history, e.g. autoimmune diseases&#xD;
Personal history, e.g. diabetes characteristics, associated co-morbidities, obstetrical history&#xD;
Clinical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of autoantibodies</measure>
    <time_frame>48 months</time_frame>
    <description>Presence, titer, specificity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Children born to mother/father with type 1 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Analysis of early immune modifications</intervention_name>
    <description>blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)&#xD;
cord blood sampling&#xD;
stool sampling in mothers and newborns at birth (day 7)&#xD;
blood and stool sampling in children at the age of 8, 18, 30 and 42 months</description>
    <arm_group_label>Children born to mother/father with type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of clinical and socio-demographic data</intervention_name>
    <description>Questionnaire filled in by clinicians at enrollment and at birth&#xD;
Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42</description>
    <arm_group_label>Children born to mother/father with type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mother and/or father with type 1 diabetes&#xD;
&#xD;
               -  age &gt; 18 years&#xD;
&#xD;
               -  type 1 diabetes : insulin-dependent diabetes positive for autoantibodies against&#xD;
                  insulin and/or GAD and/or IA-2 and/or ZnT8 at the time of diagnosis&#xD;
&#xD;
               -  planning to give birth or having given birth since less than 8 months&#xD;
&#xD;
               -  agreeing to participate upon written informed consent&#xD;
&#xD;
               -  covered by the French social security system&#xD;
&#xD;
          2. Mother/father without Type 1 diabetes&#xD;
&#xD;
               -  age &gt; 18 years old&#xD;
&#xD;
               -  with a spouse with type 1 diabetes : insulin-dependent diabetes positive for&#xD;
                  autoantibodies against insulin and/or GAD and/or IA-2 and/or ZnT8 at the time of&#xD;
                  diagnosis&#xD;
&#xD;
               -  planning to give birth or having given birth since less than 8 months&#xD;
&#xD;
               -  agreeing to participate upon written informed consent&#xD;
&#xD;
               -  covered by the French social security system&#xD;
&#xD;
          3. Children born to mother and/or father with type 1 diabetes&#xD;
&#xD;
               -  age &lt; 8 months&#xD;
&#xD;
               -  with at least one parent with T1D&#xD;
&#xD;
               -  with both parents agreeing to participate&#xD;
&#xD;
               -  both parents covered by the French social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Mother/father&#xD;
&#xD;
          -  secondary forms of diabetes&#xD;
&#xD;
          -  monogenic forms of diabetes&#xD;
&#xD;
             1 or 2) For the mother&#xD;
&#xD;
          -  malignant neoplastic or psychiatric disease&#xD;
&#xD;
             3 ) Newborns of mother/father with type 1 diabetes&#xD;
&#xD;
          -  Severe foetal disease&#xD;
&#xD;
          -  Severe congenital malformation&#xD;
&#xD;
          -  Congenital measles&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Mallone, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM U1016</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>risk assessment</keyword>
  <keyword>immunological marker</keyword>
  <keyword>children</keyword>
  <keyword>relatives</keyword>
  <keyword>autoantibodies</keyword>
  <keyword>lymphocytes</keyword>
  <keyword>T cells</keyword>
  <keyword>epitopes</keyword>
  <keyword>Children born to mother/father with type 1 diabetes and their parents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

